Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lefamulin - Nabriva Therapeutics

Drug Profile

Lefamulin - Nabriva Therapeutics

Alternative Names: BC-3781; BC-3781.Ac; Lefamulin-acetate; XENLETA

Latest Information Update: 30 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nabriva Therapeutics
  • Developer Nabriva Therapeutics; Sunovion Pharmaceuticals Canada
  • Class Alkenes; Anti-infectives; Anti-inflammatories; Antibacterials; Cyclopentanes; Diterpenes; Polycyclic compounds; Small molecules; Thioglycolates
  • Mechanism of Action Immunomodulators; Peptidyltransferase modulators; Protein 50S ribosomal subunit modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia
  • Phase II Skin and soft tissue infections
  • Preclinical Bacterial infections; Bone and joint infections; Inflammation; Nosocomial pneumonia; Osteomyelitis; Sexually transmitted infections

Most Recent Events

  • 28 Jul 2020 Registered for Community-acquired pneumonia (Treatment-experienced, In adults, Monotherapy) in European Union, Iceland, Norway, Liechtenstein (IV)
  • 28 Jul 2020 Registered for Community-acquired pneumonia (Treatment-experienced, In adults, Monotherapy) in Liechtenstein, Norway, Iceland, European Union (PO)
  • 23 Jul 2020 Preclinical trials in Inflammation in Austria (SC) before July 2020
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top